DDInter1197 DDInter1747
Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Metoclopramide {u} (Compound) resembles {v} (Compound) Cinchocaine
Metoclopramide {u} (Compound) resembles {v} (Compound) Procaine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procainamide
Metoclopramide {u} (Compound) binds {v} (Gene) DRD3
Metoclopramide {u} (Compound) palliates {v} (Disease) migraine
Metoclopramide {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Metoclopramide {u} (Compound) causes {v} (Side Effect) Somnolence
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dopamine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desvenlafaxine
Metoclopramide {u} may lead to a major life threatening interaction when taken with {v} Paliperidone
Metoclopramide (Compound) resembles Cinchocaine (Compound)
Metoclopramide (Compound) resembles Procaine (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Metoclopramide (Compound) binds DRD3 (Gene)
Metoclopramide (Compound) palliates migraine (Disease)
Metoclopramide (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Metoclopramide (Compound) causes Somnolence (Side Effect)
Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Dopamine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Metoclopramide may lead to a major life threatening interaction when taken with Paliperidone